Deficiency of the enzymes of mitochondrial fatty acid oxidation and related carnitine dependent steps have been shown to be one of the causes of the fasting-induced hypoketotic hypoglycemia. We describe here carnitine-acylcarnitine translocase deficiency in a neonate who died eight days after birth. The proband showed severe fasting-induced hypoketotic hypoglycemia, high plasma creatine kinase, heartbeat disorder, hypothermia, and hyperammonemia. The plasma-free carnitine on day three was only 3 ,M, and 92% of the total carnitine (37 ,uM) was present as acylcarnitine. Treatments with intravenous glucose, carnitine, and medium-chain triglycerides had been tried without improvements. Measurements in fibroblasts confirmed deficient oxidation of palmitate and showed normal activities of the carnitine palmitoyltransferases I and II and of the three acylCoA dehydrogenases. A total deficiency of the carnitine-acylcarnitine translocase was found in fibroblasts using the carnitine acetylation assay (1986. Biochem. J. 236:143-148). This assay has been further simplified by seeking conditions permitting application to permeabilized fibroblasts and lymphocytes. (J. Clin. Invest. 1993. 91:1247-1252
Introduction
Long-chain fatty acid oxidation contributes to energy homeostasis, especially in heart, liver, and skeletal muscle. In the myocardium, long-chain fatty acids are the preferred substrates in the resting state (1) . In the liver, oxidation of long-chain fatty acid produces ketone bodies, enhances gluconeogenesis, and thereby allows the maintenance of normoglycemia during fasting (2) . In the skeletal muscle, oxidation oflong-chain fatty acid is the major source of energy both in the resting state (3) and during prolonged exercise. Inborn errors of mitochondrial long-chain fatty acid oxidation give rise to a number of symptoms, mostly hypoketotic hypoglycemia, cardiac injury, and skeletal myopathy. These symptoms result from an abnormal metabolite buildup proximal to the enzyme defect and from deficient formation of energy-yielding substrates after the block (4). 10 hereditary defects of mitochondrial long-chain fatty acid catabolism have been described with various clinical phenotypes, ranging from malformations and sudden infant death to nearly asymptomatic adult. Six of these involve enzymes of intramitochondrial beta-oxidation itself, namely long-chain acylCoA dehydrogenase (5), 3-hydroxy long-chain acylCoA dehydrogenase (6) , electron transfer flavoprotein (7), electron transfer flavoprotein dehydrogenase (7), trifunctional enzyme (8) and 2-4 dienoylCoA reductase (9) . Four others affect the carnitine shuttle for the transport of longchain fatty acids into the mitochondria; these involve either intracellular uptake of carnitine ( 10) or the enzymes carnitine palmitoyl transferase (CPT) I and 11 ( I 1-1 3). The possibility that a deficiency of the carnitine-acylcarnitine translocase might occur has been speculated for some time, but direct evidence has been obtained in only one case recently ( 14) . The carnitine-acylcarnitine translocase is an inner mitochondrial membrane protein that allows the passage of carnitine and acylcarnitines across the inner mitochondrial membrane ( 15) . Herein, we report a neonatal case of carnitine-acylcarnitine translocase deficiency with severe hypoketotic hypoglycemia, hyperammonemia, and auriculo-ventricular block. In all cases of long-chain fatty acid oxidation disorders, it is interesting to correlate the clinical expression of the different defects to the metabolic profile and to the residual enzyme activity. In this regard, we note that the symptomatology of the present neartotal translocase-deficient patient closely matches that seen in the infantile form of CPT II deficiency where a severe loss of the CPT II activity occurs ( 13) .
Methods
Case report. C.O. was a male infant, weighing 2.6 kg, 51 cm long, with a 33 cm head circumference, born after an uncomplicated full-term pregnancy and normal delivery to healthy Turkish parents who are first cousins. Two living brothers born in 1975 and in 1990 are healthy. Two other sibs, a boy and a girl, died within the first six months of life in Turkey; their clinical and medical data were unavailable.
Breast-feeding was started immediately after birth. At 36 h of life, the infant was found hypothermic (temperature 34.5"C), pale, without reactivity, and severely hypoglycemic (dextrostix nil). After intravenous administration of glucose was started, he was transferred to the intensive care unit. At admission, temperature was 35.40C. The general condition was very serious, with diaphanous gray, mottled skin, profuse sweating, moderate general hypotonia with fluctuating muscle, hypo-and hypertonicity but normal consciousness, normal provoked reactivity, normal cry, normal primitive reflexes, and no abnormal movements. Heart rate was regular ( 140/min) with normal peripheral pulses; blood pressure was 40 mmHg. There was no hepatosplenomegaly. Initial laboratory data, at admission, (normal values in parentheses) were: plasma glucose 2.24 mmol/liter (3.5-6 mmol/liter), calcium 2 mmol/liter (2-2.6), normal blood electrolytes, arterial pH 7.40, PCO2 34 mmHg, bicarbonate 22 meq/liter, normal blood cell count. After a 1-h initial improvement while receiving continuously 10% glucose i.v., 15 ml 20% albumin solution i.v. and 40 ml vamine (10% glucose and 7% amino acid solution), hypoglycemia fell again to 1 mmol/liter with gray-colored skin, generalized hypotonia, bradycardia at 65/min, first degree auriculo-ventricular block (PR 200 ms) and left bundle branch block (see Fig. 1 with esterified/total ratio 92% ( < 30%). Plasma and urine amino acid chromatography was normal, and so was the organic acid profile determined by GC-MS in analyses performed at the time patient was hyperammonemic. Orotic acid excretion was 2.7 Mmol/mmol creatinine (0.5-3). Acetest was negative. At this time, urea cycle defect was considered, and patient began treatment with arginine, sodium benzoate, carnitine, and protein withdrawal.
Despite were performed in 24 well microtiter plates, as described in (17) . Briefly, 50,000 cells per well were plated in HAM F1O medium. After 48 h, the cells were washed, and the monolayers were incubated with 100 ,uM [9, 10(n)-3H]palmitate (specific activity 75 Ci/mol) bound to albumin (0.5 mg/ml) in 0.2 ml of Dulbecco's phosphate buffered saline with 0.9 mM Ca2" and 0.5 mM Mg2". Blank wells without cells were run in parallel. Tritiated water was recovered by ion exchange treatment on Dowex-1 columns (17) . The activity showed linearity with 10 to 50 Mg protein per well for up to at least 4 h of incubation.
Carnitine-acylcarnitine translocase assay. The method as described in (18) 30 'C. Linearity was observed for up to about 10% acetyl-CoA used up. Reactions were stopped by adding 800 ,l ofchilled water and about 300±20 mg of AG 2-X 8 resin (C1-form, 200-400 mesh); for convenience, resin addition was made using a 1-ml tuberculin syringe as in (19) . The tubes were vortexed twice, left for about 10 min, briefly centrifuged; the radioactivity of the supernatant was then determined.
Protein estimation. In the fatty acid oxidation experiments, protein content ofeach well was determined (20) after solubilization ofthe cell material in 1 M NaOH. During assay of the translocase, protein was estimated using the BCA reagent of Pierce Chemical Co. (Rockford, IL); the supplier's protocol was followed with the following modification. The fibroblast suspension in mannitol-Hepes was supplemented with Triton X-100 (1%, vol/vol), and after vigorous vortexing the tubes were left at room temperature for at least 10 min to solubilize protein prior to the addition of the BCA reagent. Mannitol-Hepes and Triton X-100 were included both in the reagent blanks and the bovine serum albumin standards.
Chemicals. Carnitine was a gift from Sigma-Tau (Pomezia, Italy); [2- 
Results
The severe hypoketotic hypoglycemia in the proband pointed to a likely defect in fatty acid oxidation. Measurements of fatty acid oxidation in the patient's fibroblasts confirmed this; the production of '4CO2 from [1-'4C palmitate and 3H20 release from [9, l0(n)-3H]palmitate were decreased by more than 95% of the mean control value (Table I ). The oxidation of [1-14C ] octanoate, which does not require carnitine-dependent steps, was normal. The impaired palmitate oxidation was not corrected by the inclusion of 1 mM carnitine (data not shown). The possibility of systemic or severe carnitine deficiency in the proband was further excluded by the observation that the total plasma carnitine level was 37 ,uM. However, an unusually high fraction (92%) of the total carnitine was present as acylcarnitine (see case report). Measurements of the CPT activities in the fibroblasts ofthe proband showed that the activities ofboth (21 ) .
In earlier experiments, we allowed a 15-min prior incubation of the fibroblast with digitonin at 30°C to allow complete cell permeabilization before the commencement ofthe translocase assay by pyruvate addition. Subsequent work showed that identical results were obtained regardless ofwhether prior incubations were allowed or not. The assay procedure was therefore simplified by adding fibroblasts directly to an otherwise complete incubation system. Good linearity was obtained with respect to the quantity ofthe fibroblast protein and the assay time under these conditions (Fig. 2) .
The following additional observations helped establish that the carnitine acetylation approach could reliably be used for the assay oftranslocase in fibroblasts (a) the activity was totally dependent on added carnitine, (b) the 0.5 mM carnitine that was recommended as a below saturating concentration during assay with human muscle homogenates to ensure that the translocase activity itself limited the rates of carnitine acetylation ( 18) was also found subsaturating with fibroblasts (activity was much higher with 10 mM carnitine, Table II), (c) the activity was fully inhibited by sulfobetaine8, a translocase inhibitor (22), (d) the rates of carnitine acetyltransferase and pyruvate oxidation reactions with the different cell lines were adequate so as not to limit the translocase activity observed with 0.5 mM carnitine (Table II) .
The carnitine-acylcarnitine translocase activity was measured in fibroblasts of normal controls and patients with known and unknown (B-oxidation defects. The results showed that the activity of the translocase was normal in patients with defects of CPT I, CPT II, long-chain acyl-CoA dehydrogenase, medium-chain acyl-CoA dehydrogenase, and in a patient with still unidentified mitochondrial fatty acid oxidation defect (Table II). No translocase activity was found in the fibroblasts of the proband (Table II) , and this remained so even after inclusion of the dithiothreitol during assay (data not shown). The effect of dithiothreitol was tested in view of the report that dithiothreitol restores to normal the decreased translocase activity seen in ischemic heart (23) .
The present translocase assay is based on the oxidation of [2-4C] pyruvate to [14C ] acetyl-CoA and the conversion ofthe latter to ['4C] acetylcarnitine. This process includes participation of the pyruvate oxidase system and the carnitine acetyltransferase. Any deficiency in the overall acetylation of carnitine can therefore be ascribed to translocase deficiency only if the other participating activities are normal. Table II shows that this was the case as in the proband the activity of carnitine acetyltransferase and pyruvate oxidase system were normal. Thus, with 0.5 mM carnitine in the incubation system, the carnitine acetylation procedure proved reliable for the assay of the carnitine-acylcarnitine translocase in fibroblasts as shown earlier for the human muscle ( 18 ) .
Discussion
We have identified here a case ofcamitine-acylcarnitine translocase deficiency in a neonate who died a week after birth. This disorder was recognized later by analyses in fibroblasts, and the diagnosis explains why attempts to manage the recurrent severe hypoglycemia by providing triglycerides and carnitine and the persistent hyperammonemia by providing benzoate had proved futile.
The occurrence of carnitine-acylcarnitine translocase deficiency as a clinical entity has been speculated earlier based on indirect evidences (24, reviewed in 25) . Only recently has this activity been assayed directly by the carnitine acetylation procedure (18) to support the conclusion that its deficiency indeed occurs (14) . Our present work, where the reliability of the carnitine acetylation procedure for translocase assay in fibroblast has been rigorously verified, clearly establishes translocase deficiency in our patient. We have emphasized previously that the conventional assays, based on the uptake or efflux of metabolites as frequently used, are not suitable for clinical work because of the misleading results that they can give ( 18, 26) . For the carnitine-acylcarnitine translocase an approach that overcame the limitations of the conventional assays was developed and validated for muscles ( 18) . In the present work, we have markedly simplified this assay particularly by extending its use to permeabilized fibroblasts. In preliminary experiments, we found that the same digitonin permeabilization procedure enables the translocase assay also in lymphocytes. Availability of these methods should now enormously simplify the clinical screening for translocase deficiency in suspected patients and their pedigree. The present findings have helped resolve some questions concerning this translocase. Thus, whether the transport of short-and long-chain acylcarnitines involves one translocase protein with broad chain-length specificity or more than one translocase with narrower chain-length specificity has remained uncertain. Here, as described previously ( 14), the deficiency ofthe translocase was found using an assay based on the measurement of the transmitochondrial transport of carnitine and acetylcarnitine, whereas the defect in fatty acid oxidation was identified as that for long-chain fatty acid, palmitate. In our patient, as in the case of Stanley et al. ( 14) , acylcarnitines accumulated to an abnormally high level (as 92% of the total plasma carnitine in our patient); moreover, the data of Stanley et al. ( 14) showed that this increase occurred in both the shortand the long-chain acylcarnitines. These findings show that the same transporter in vivo catalyzes the transport of both the short-and the long-chain acylcarnitines. This is consistent with the observation that a purified translocase preparation from rat liver mitochondria shows activity with short-as well as longchain acylcarnitines (27) . Moreover, as the translocase deficiency in fibroblasts has been found in patients showing signs of hepatic (lack of ketone bodies) cardiac (cardiomyopathy, heartbeat disorder) and muscular (creatine kinase) defects, the disorder identified seems to involve defect of the same protein in the different tissues mentioned.
Whereas the relationship of the translocase deficiency to severe hypoglycemia, seen in our patient, is understandable in view of the known role of fatty acid oxidation in supporting gluconeogenesis and in sparing glucose oxidation, its relationship to hyperammonemia, seen in our patient, as in ( 14), remains intriguing. Hyperammonemia has also been frequently observed in long-chain fatty acid oxidation defects presenting as Reye's syndrome (28, 29) . It is possible that a severely curtailed fatty acid oxidation in liver causes an energy deficit intramitochondrially resulting in impaired ureagenesis and hyperammonia.
The striking cardiac abnormalities seen in our translocase deficient patient (Fig. I ) were similar to those identified earlier in the infantile form of(severe) CPT II deficiency ( 13) . In both these disorders a marked buildup of acylcarnitines is to be expected, and the cardiac abnormalities could have arisen from the known toxicity of long-chain acylcarnitines (30) . Longchain fatty acid oxidation defects with such an accumulation of acylcarnitine (not only in CPT II and translocase but also in long-chain and 3-hydroxy long-chain acyl-CoA dehydrogenases) should be therefore systematically considered in neonates and infants presenting cardiac arrest, unexpected collapse, or heart trouble, symptoms that otherwise can easily lead to the misdiagnosis of toxic shock, sudden death, or malignant hyperthermia.
